Sector & Market
Enliven Therapeutics CFO Sells $316.8K Stock
CFO Benjamin Hohl sold 6,018 shares for $316,780 on July 17, 2026 via a Rule 10b5‑1 plan, at $49.97‑$53.87 per share.
Prior to sale, Hohl exercised options for 1,072 shares at $2.48 each, and now hold
